Cyclerion Therapeutics Stock Analysis
CYCN Stock | USD 2.20 0.04 1.85% |
Cyclerion Therapeutics is undervalued with Real Value of 2.56 and Target Price of 4.0. The main objective of Cyclerion Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Cyclerion Therapeutics is worth, separate from its market price. There are two main types of Cyclerion Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Cyclerion Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Cyclerion Therapeutics is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. Cyclerion Stock trading window is adjusted to America/New York timezone.
Cyclerion |
Cyclerion Stock Analysis Notes
About 22.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.73. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cyclerion Therapeutics recorded a loss per share of 2.08. The entity had not issued any dividends in recent years. The firm had 1:20 split on the 16th of May 2023. Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system diseases. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Cyclerion Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 32 people. For more info on Cyclerion Therapeutics please contact Peter Hecht at 857 327 8778 or go to https://www.cyclerion.com.Cyclerion Therapeutics Investment Alerts
Cyclerion Therapeutics had very high historical volatility over the last 90 days | |
Cyclerion Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
Net Loss for the year was (5.26 M) with loss before overhead, payroll, taxes, and interest of (29.75 M). | |
Cyclerion Therapeutics currently holds about 30.32 M in cash with (21.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.7. | |
Cyclerion Therapeutics has a poor financial position based on the latest SEC disclosures | |
Roughly 22.0% of the company shares are held by company insiders | |
Latest headline from news.google.com: Disposition of 357880 shares by Slate Path Capital Lp of Cyclerion Therapeutics at 1.5511 subject to Rule 16b-3 |
Cyclerion Therapeutics Upcoming and Recent Events
Earnings reports are used by Cyclerion Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
27th of March 2024 Upcoming Quarterly Report | View | |
31st of December 2023 Next Fiscal Quarter End | View |
Cyclerion Largest EPS Surprises
Earnings surprises can significantly impact Cyclerion Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2022-02-24 | 2021-12-31 | -0.3 | -0.33 | -0.03 | 10 | ||
2022-05-04 | 2022-03-31 | -0.36 | -0.3 | 0.06 | 16 | ||
2022-11-03 | 2022-09-30 | -0.31 | -0.24 | 0.07 | 22 |
Cyclerion Therapeutics Environmental, Social, and Governance (ESG) Scores
Cyclerion Therapeutics' ESG score is a quantitative measure that evaluates Cyclerion Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Cyclerion Therapeutics' operations that may have significant financial implications and affect Cyclerion Therapeutics' stock price as well as guide investors towards more socially responsible investments.
Cyclerion Stock Institutional Investors
Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.3 K | Group One Trading, Lp | 2024-06-30 | 540 | Royal Bank Of Canada | 2024-06-30 | 416 | Activest Wealth Management | 2024-06-30 | 100.0 | Bank Of America Corp | 2024-06-30 | 16.0 | Northwestern Mutual Wealth Management Co | 2024-06-30 | 1.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Farmers National Bank | 2024-06-30 | 0.0 | Pnc Financial Services Group Inc | 2024-09-30 | 0.0 | Slate Path Capital Lp | 2024-09-30 | 357.9 K | Mfn Partners Management, Lp | 2024-06-30 | 169.5 K |
Cyclerion Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.96 M.Cyclerion Profitablity
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (1.57) | (1.65) | |
Return On Capital Employed | (0.85) | (0.81) | |
Return On Assets | (1.57) | (1.65) | |
Return On Equity | (1.86) | (1.77) |
Management Efficiency
Cyclerion Therapeutics has return on total asset (ROA) of (0.4655) % which means that it has lost $0.4655 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.5025) %, meaning that it created substantial loss on money invested by shareholders. Cyclerion Therapeutics' management efficiency ratios could be used to measure how well Cyclerion Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 1st of December 2024, Return On Tangible Assets is likely to drop to -1.65. In addition to that, Return On Capital Employed is likely to grow to -0.81. At this time, Cyclerion Therapeutics' Non Currrent Assets Other are very stable compared to the past year. As of the 1st of December 2024, Asset Turnover is likely to grow to 0.02, while Total Assets are likely to drop about 12.7 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | 4.83 | 4.59 | |
Tangible Book Value Per Share | 4.83 | 4.59 | |
Enterprise Value Over EBITDA | (0.02) | (0.02) | |
Price Book Value Ratio | 0.69 | 0.73 | |
Enterprise Value Multiple | (0.02) | (0.02) | |
Price Fair Value | 0.69 | 0.73 |
Cyclerion Therapeutics showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Beta 1.924 | Return On Assets (0.47) | Return On Equity (1.50) |
Technical Drivers
As of the 1st of December, Cyclerion Therapeutics shows the risk adjusted performance of 0.0367, and Mean Deviation of 7.0. Cyclerion Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.Cyclerion Therapeutics Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Cyclerion Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Cyclerion Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Cyclerion Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cyclerion Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cyclerion Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cyclerion Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cyclerion Therapeutics Outstanding Bonds
Cyclerion Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cyclerion Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cyclerion bonds can be classified according to their maturity, which is the date when Cyclerion Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp BondUS235822AB96 | View | |
Volcan Compania Minera Corp BondUSP98047AC08 | View | |
Boeing Co 2196 Corp BondUS097023DG73 | View | |
HSBC Holdings PLC Corp BondUS404280DR76 | View | |
MPLX LP 52 Corp BondUS55336VAL45 | View | |
Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
MGM Resorts International Corp BondUS552953CD18 | View |
Cyclerion Therapeutics Predictive Daily Indicators
Cyclerion Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Cyclerion Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Cyclerion Therapeutics Corporate Filings
F4 | 25th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 14th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
10Q | 7th of August 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
13A | 12th of July 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 14th of June 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 7th of May 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
29th of April 2024 Other Reports | ViewVerify | |
8K | 18th of April 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Cyclerion Therapeutics Forecast Models
Cyclerion Therapeutics' time-series forecasting models are one of many Cyclerion Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cyclerion Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Cyclerion Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Cyclerion Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cyclerion shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Cyclerion Therapeutics. By using and applying Cyclerion Stock analysis, traders can create a robust methodology for identifying Cyclerion entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (170.67) | (162.14) | |
Operating Profit Margin | (171.81) | (163.22) | |
Net Loss | (169.53) | (161.06) | |
Gross Profit Margin | 0.78 | 0.90 |
Current Cyclerion Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Cyclerion analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Cyclerion analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
4.0 | Strong Buy | 1 | Odds |
Most Cyclerion analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Cyclerion stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Cyclerion Therapeutics, talking to its executives and customers, or listening to Cyclerion conference calls.
Cyclerion Stock Analysis Indicators
Cyclerion Therapeutics stock analysis indicators help investors evaluate how Cyclerion Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Cyclerion Therapeutics shares will generate the highest return on investment. By understating and applying Cyclerion Therapeutics stock analysis, traders can identify Cyclerion Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow | 13.4 M | |
Common Stock Shares Outstanding | 2.3 M | |
Total Stockholder Equity | 11.3 M | |
Cash And Short Term Investments | 7.6 M | |
Cash | 7.6 M | |
Accounts Payable | 1.2 M | |
Net Debt | -7.6 M | |
50 Day M A | 2.4725 | |
Total Current Liabilities | 2.1 M | |
Other Operating Expenses | 9.6 M | |
Non Current Assets Total | 5.3 M | |
Non Currrent Assets Other | 5.3 M | |
Stock Based Compensation | 1.1 M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclerion Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Cyclerion Stock, please use our How to Invest in Cyclerion Therapeutics guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclerion Therapeutics. If investors know Cyclerion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclerion Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Revenue Per Share 0.586 | Quarterly Revenue Growth 0.141 | Return On Assets (0.47) | Return On Equity (1.50) |
The market value of Cyclerion Therapeutics is measured differently than its book value, which is the value of Cyclerion that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclerion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclerion Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclerion Therapeutics' market value can be influenced by many factors that don't directly affect Cyclerion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclerion Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclerion Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclerion Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.